Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 31
Filter
2.
Am J Transplant ; 15(6): 1644-53, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25649117

ABSTRACT

Tofacitinib fixed-dose regimens attained better kidney function and comparable efficacy to cyclosporine (CsA) in kidney transplant patients, albeit with increased risks of certain adverse events. This post-hoc analysis evaluated whether a patient subgroup with an acceptable risk-benefit profile could be identified. Tofacitinib exposure was a statistically significant predictor of serious infection rate. One-hundred and eighty six kidney transplant patients were re-categorized to above-median (AME) or below-median (BME) exposure groups. The 6-month biopsy-proven acute rejection rates in AME, BME and CsA groups were 7.8%, 15.7% and 17.7%, respectively. Measured glomerular filtration rate was higher in AME and BME groups versus CsA (61.2 and 67.9 vs. 53.9 mL/min) at Month 12. Fewer patients developed interstitial fibrosis and tubular atrophy (IF/TA) at Month 12 in AME (20.5%) and BME (27.8%) groups versus CsA (48.3%). Serious infections occurred more frequently in the AME group (53.0%) than in BME (28.4%) or CsA (25.5%) groups. Posttransplant lymphoproliferative disorder (PTLD) only occurred in the AME group. In kidney transplant patients, the BME group preserved the clinical advantage of comparable acute rejection rates, improved renal function and a lower incidence of IF/TA versus CsA, and with similar rates of serious infection and no PTLD.


Subject(s)
Graft Rejection/prevention & control , Immunosuppressive Agents/adverse effects , Kidney Transplantation , Kidney/physiopathology , Piperidines/adverse effects , Pyrimidines/adverse effects , Pyrroles/adverse effects , Adult , Biopsy , Cyclosporine/adverse effects , Cyclosporine/pharmacology , Cyclosporine/therapeutic use , Dose-Response Relationship, Drug , Female , Glomerular Filtration Rate/drug effects , Glomerular Filtration Rate/physiology , Graft Rejection/epidemiology , Humans , Immunosuppressive Agents/pharmacology , Immunosuppressive Agents/therapeutic use , Kidney/drug effects , Kidney/pathology , Lymphoproliferative Disorders/epidemiology , Male , Middle Aged , Piperidines/pharmacology , Piperidines/therapeutic use , Pyrimidines/pharmacology , Pyrimidines/therapeutic use , Pyrroles/pharmacology , Pyrroles/therapeutic use , Randomized Controlled Trials as Topic , Risk Assessment , Risk Factors
3.
Am J Transplant ; 15(3): 695-704, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25693475

ABSTRACT

Thirty-eight HLA matched and mismatched patients given combined living donor kidney and enriched CD34(+) hematopoietic cell transplants were enrolled in tolerance protocols using posttransplant conditioning with total lymphoid irradiation and anti-thymocyte globulin. Persistent chimerism for at least 6 months was associated with successful complete withdrawal of immunosuppressive drugs in 16 of 22 matched patients without rejection episodes or kidney disease recurrence with up to 5 years follow up thereafter. One patient is in the midst of withdrawal and five are on maintenance drugs. Persistent mixed chimerism was achieved in some haplotype matched patients for at least 12 months by increasing the dose of T cells and CD34(+) cells infused as compared to matched recipients in a dose escalation study. Success of drug withdrawal in chimeric mismatched patients remains to be determined. None of the 38 patients had kidney graft loss or graft versus host disease with up to 14 years of observation. In conclusion, complete immunosuppressive drug withdrawal could be achieved thus far with the tolerance induction regimen in HLA matched patients with uniform long-term graft survival in all patients.


Subject(s)
Chimerism , Graft Survival , Hematopoietic Stem Cell Transplantation , Immunosuppressive Agents/administration & dosage , Kidney Transplantation , Living Donors , Adult , Cohort Studies , Female , Humans , Male , Middle Aged , Young Adult
4.
Transplant Proc ; 45(1): 82-7, 2013.
Article in English | MEDLINE | ID: mdl-23375278

ABSTRACT

Sensitization remains a major barrier to kidney transplantation. Sensitized patients comprise 30% of the kidney transplant waiting list but fewer than 15% of highly sensitized patients are transplanted each year. Options for highly sensitized patients with an immunologically incompatible living donor include desensitization or kidney paired donation (KPD). However, these options when used alone may still not be sufficient to allow a compatible transplant for recipients who are broadly sensitized with cumulative calculated panel-reactive antibody (cPRA) > 95%. We describe in this report the combined use of both desensitization and KPD to maximize the likelihood of finding a compatible match with a more immunologically favorable donor through a kidney exchange program. This combined approach was used in five very highly sensitized patients, all with cPRA 100%, who ultimately received compatible living and deceased donor kidney transplants. We conclude that early enrollment in paired kidney donor exchange and tailored desensitization protocols are key strategies to improve care and rates of kidney transplantation in highly sensitized patients.


Subject(s)
Desensitization, Immunologic/methods , Graft Survival/immunology , Kidney Failure, Chronic/therapy , Kidney Transplantation/immunology , Living Donors , Tissue and Organ Procurement/methods , Adult , Algorithms , Antibodies/immunology , Female , Graft Rejection/immunology , HLA Antigens/immunology , Histocompatibility , Histocompatibility Testing , Humans , Kidney/immunology , Kidney Failure, Chronic/immunology , Kidney Failure, Chronic/surgery , Male , Middle Aged
5.
Am J Transplant ; 12(9): 2429-36, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22812922

ABSTRACT

We report the results of a large series of chain transplantations that were facilitated by a multicenter US database in which 57 centers pooled incompatible donor/recipient pairs. Chains, initiated by nondirected donors, were identified using a computer algorithm incorporating virtual cross-matches and potential to extend chains. The first 54 chains facilitated 272 kidney transplants (mean chain length = 5.0). Seven chains ended because potential donors became unavailable to donate after their recipient received a kidney; however, every recipient whose intended donor donated was transplanted. The remaining 47 chains were eventually closed by having the last donor donate to the waiting list. Of the 272 chain recipients 46% were ethnic minorities and 63% of grafts were shipped from other centers. The number of blood type O-patients receiving a transplant (n = 90) was greater than the number of blood type O-non-directed donors (n = 32) initiating chains. We have 1-year follow up on the first 100 transplants. The mean 1-year creatinine of the first 100 transplants from this series was 1.3 mg/dL. Chain transplantation enables many recipients with immunologically incompatible donors to be transplanted with high quality grafts.


Subject(s)
Kidney Transplantation , Algorithms , Female , Humans , Male , Treatment Outcome , United States
6.
Am J Transplant ; 12(9): 2446-56, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22682022

ABSTRACT

In this Phase 2b study, 331 low-to-moderate risk de novo kidney transplant patients (approximately 60% deceased donors) were randomized to a more intensive (MI) or less intensive (LI) regimen of tofacitinib (CP-690, 550), an oral Janus kinase inhibitor or cyclosporine (CsA). All patients received basiliximab induction, mycophenolic acid and corticosteroids. Primary endpoints were: incidence of biopsy-proven acute rejection (BPAR) with a serum creatinine increase of ≥0.3 mg/dL and ≥20% (clinical BPAR) at Month 6 and measured GFR at Month 12. Similar 6-month incidences of clinical BPAR (11%, 7% and 9%) were observed for MI, LI and CsA. Measured GFRs were higher (p < 0.01) at Month 12 for MI and LI versus CsA (65 mL/min, 65 mL/min vs. 54 mL/min). Fewer (p < 0.05) patients in MI or LI developed chronic allograft nephropathy at Month 12 compared with CsA (25%, 24% vs. 48%). Serious infections developed in 45%, 37% and 25% of patients in MI, LI and CsA, respectively. Anemia, neutropenia and posttransplant lymphoproliferative disorder occurred more frequently in MI and LI compared with CsA. Tofacitinib was equivalent to CsA in preventing acute rejection, was associated with improved renal function and less chronic allograft histological injury, but had side-effects at the doses evaluated.


Subject(s)
Immunosuppressive Agents/therapeutic use , Janus Kinase 3/antagonists & inhibitors , Kidney Transplantation , Protein Kinase Inhibitors/therapeutic use , Pyrimidines/therapeutic use , Pyrroles/therapeutic use , Adult , Female , Humans , Immunosuppressive Agents/adverse effects , Immunosuppressive Agents/pharmacokinetics , Male , Middle Aged , Piperidines , Protein Kinase Inhibitors/adverse effects , Protein Kinase Inhibitors/pharmacokinetics , Pyrimidines/adverse effects , Pyrimidines/pharmacokinetics , Pyrroles/adverse effects , Pyrroles/pharmacokinetics
7.
Am J Transplant ; 12(5): 1133-45, 2012 May.
Article in English | MEDLINE | ID: mdl-22405058

ABSTRACT

Sixteen patients conditioned with total lymphoid irradiation (TLI) and antithymocyte globulin (ATG) were given kidney transplants and an injection of CD34+ hematopoietic progenitor cells and T cells from HLA-matched donors in a tolerance induction protocol. Blood cell monitoring included changes in chimerism, balance of T-cell subsets and responses to donor alloantigens. Fifteen patients developed multilineage chimerism without graft-versus-host disease (GVHD), and eight with chimerism for at least 6 months were withdrawn from antirejection medications for 1-3 years (mean, 28 months) without subsequent rejection episodes. Four chimeric patients have just completed or are in the midst of drug withdrawal, and four patients were not withdrawn due to return of underlying disease or rejection episodes. Blood cells from all patients showed early high ratios of CD4+CD25+ regulatory T cells and NKT cells versus conventional naive CD4+ T cells, and those off drugs showed specific unresponsiveness to donor alloantigens. In conclusion, TLI and ATG promoted the development of persistent chimerism and tolerance in a cohort of patients given kidney transplants and hematopoietic donor cell infusions. All 16 patients had excellent graft function at the last observation point with or without maintenance drugs.


Subject(s)
Graft Survival/immunology , Graft vs Host Disease/prevention & control , Hematopoietic Stem Cell Transplantation , Immunosuppressive Agents/therapeutic use , Kidney Transplantation , Transplantation Immunology , Adult , Antilymphocyte Serum/therapeutic use , Blood Group Incompatibility , Female , Fluorescent Antibody Technique , Graft vs Host Disease/immunology , Humans , Immune Tolerance , Lymphatic Irradiation , Male , Middle Aged , Transplantation Chimera , Treatment Outcome , Young Adult
8.
Am J Transplant ; 11(12): 2675-84, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21943027

ABSTRACT

Voclosporin (VCS, ISA247) is a novel calcineurin inhibitor being developed for organ transplantation. PROMISE was a 6-month, multicenter, randomized, open-label study of three ascending concentration-controlled groups of VCS (low, medium and high) compared to tacrolimus (TAC) in 334 low-risk renal transplant recipients. The primary endpoint was demonstration of noninferiority of biopsy proven acute rejection (BPAR) rates. Secondary objectives included renal function, new onset diabetes after transplantation (NODAT), hypertension, hyperlipidemia and pharmacokinetic-pharmacodynamic evaluation. The incidence of BPAR in the VCS groups (10.7%, 9.1% and 2.3%, respectively) was noninferior to TAC (5.8%). The incidence of NODAT for VCS was 1.6%, 5.7% and 17.7% versus 16.4% in TAC (low-dose VCS, p = 0.03). Nankivell estimated glomerular filtration rate was respectively: 71, 72, 68 and 69 mL/min, statistically lower in the high-dose group, p = 0.049. The incidence of hypertension and adverse events was not different between the VCS groups and TAC. VCS demonstrated an excellent correlation between trough and area under the curve (r(2) = 0.97) and no difference in mycophenolic acid exposure compared to TAC. This 6-month study shows VCS to be as efficacious as TAC in preventing acute rejection with similar renal function in the low- and medium-exposure groups, and potentially associated with a reduced incidence of NODAT.


Subject(s)
Cyclosporine/adverse effects , Graft Rejection/chemically induced , Immunosuppressive Agents/adverse effects , Kidney Failure, Chronic/therapy , Kidney Transplantation , Postoperative Complications , Tacrolimus/adverse effects , Cardiovascular Diseases/chemically induced , Cardiovascular Diseases/epidemiology , Cardiovascular Diseases/mortality , Diabetes Complications/chemically induced , Diabetes Complications/epidemiology , Diabetes Complications/mortality , Female , Glomerular Filtration Rate , Graft Rejection/epidemiology , Graft Rejection/mortality , Graft Survival , Humans , Hypertension/chemically induced , Hypertension/epidemiology , Hypertension/mortality , Incidence , Kidney Failure, Chronic/complications , Kidney Function Tests , Male , Middle Aged , Survival Rate
9.
Am J Transplant ; 11(9): 1810-4, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21831153

ABSTRACT

Kidney donor exchanges enable recipients with immunologically incompatible donors to receive compatible living donor grafts; however, the financial management of these exchanges, especially when an organ is shipped, is complex and thus has the potential to impede the broader implementation of donor exchange programs. Representatives from transplant centers that utilize the National Kidney Registry database to facilitate donor exchange transplants developed a financial model applicable to paired donor exchanges and donor chain transplants. The first tenet of the model is to eliminate financial liability to the donor. Thereafter, it accounts for the donor evaluation, donor nephrectomy hospital costs, donor nephrectomy physician fees, organ transport, donor complications and recipient inpatient services. Billing between hospitals is based on Medicare cost report defined costs rather than charges. We believe that this model complies with current federal regulations and effectively captures costs of the donor and recipient services. It could be considered as a financial paradigm for the United Network for Organ Sharing managed donor exchange program.


Subject(s)
Costs and Cost Analysis , Kidney Transplantation , Living Donors , Transportation/economics , Humans , Models, Economic
10.
Am J Transplant ; 9(8): 1936-45, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19660021

ABSTRACT

This randomized, pilot study compared the Janus kinase inhibitor CP-690,550 (15 mg BID [CP15] and 30 mg BID [CP30], n = 20 each) with tacrolimus (n = 21) in de novo kidney allograft recipients. Patients received an IL-2 receptor antagonist, concomitant mycophenolate mofetil (MMF) and corticosteroids. CP-690,550 doses were reduced after 6 months. Due to a high incidence of BK virus nephropathy (BKN) in CP30, MMF was discontinued in this group. The 6-month biopsy-proven acute rejection rates were 1 of 20, 4 of 20 and 1 of 21 for CP15, CP30 and tacrolimus groups, respectively. BKN developed in 4 of 20 patients in CP30 group. The 6-month rates of cytomegalovirus disease were 2 of 20, 4 of 20 and none of 21 for CP15, CP30 and tacrolimus groups, respectively. Estimated glomerular filtration rate was >70 mL/min at 6 and 12 months (all groups). NK cells were reduced by

Subject(s)
Calcineurin Inhibitors , Graft Rejection/prevention & control , Immunosuppressive Agents/therapeutic use , Janus Kinases/antagonists & inhibitors , Kidney Transplantation/immunology , Mycophenolic Acid/analogs & derivatives , Pyrimidines/therapeutic use , Pyrroles/therapeutic use , Adrenal Cortex Hormones/adverse effects , Adrenal Cortex Hormones/therapeutic use , Adult , Aged , Biopsy , Dose-Response Relationship, Drug , Drug Therapy, Combination , Female , Follow-Up Studies , Glomerular Filtration Rate/physiology , Graft Rejection/immunology , Humans , Immunosuppressive Agents/adverse effects , Kaplan-Meier Estimate , Kidney/pathology , Kidney/physiopathology , Kidney Transplantation/pathology , Kidney Transplantation/physiology , Male , Middle Aged , Mycophenolic Acid/adverse effects , Mycophenolic Acid/therapeutic use , Pilot Projects , Piperidines , Pyrimidines/adverse effects , Pyrroles/adverse effects , Tacrolimus/adverse effects , Tacrolimus/therapeutic use , Transplantation, Homologous , Young Adult
11.
Am J Transplant ; 9(9): 2180-5, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19563335

ABSTRACT

The organ donor shortage has been the most important hindrance in getting listed patients transplanted. Living kidney donors who are incompatible with their intended recipients are an untapped resource for expanding the donor pool through participation in transplant exchanges. Chain transplantation takes this concept further, with the potential to benefit even more recipients. We describe the first asynchronous, out of sequence transplant chain that was initiated by transcontinental shipment of an altruistic donor kidney 1 week after that recipient's incompatible donor had already donated his kidney to the next recipient in the chain. The altruistic donor kidney was transported from New York to Los Angeles and functioned immediately after transplantation. Our modified-sequence asynchronous transplant chain (MATCH) enabled eight recipients, at four different institutions, to benefit from the generosity of one altruistic donor and warrants further exploration as a promising step toward addressing the organ donor shortage.


Subject(s)
ABO Blood-Group System , Blood Group Incompatibility , Kidney Transplantation/methods , Tissue and Organ Procurement , Adult , Altruism , Creatinine/blood , Female , Humans , Living Donors , Male , Middle Aged , Quality of Life , Transplantation, Homologous , United States
12.
Transplant Proc ; 40(2): 375-8, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18374073

ABSTRACT

Strategies inhibiting cell death signaling pathways may enhance the availability of islet transplantation for patients with type 1 diabetes mellitus. The epsilon isoform of protein kinase C (PKC epsilon) has been shown to have an anti-apoptotic effect in many cell types. The present study investigated whether activation of PKC epsilon may improve the yield of functional islet cells for transplantation. Islet cells were isolated from wild-type BALB/c mice preconditioned with either a PKC epsilon activator (psi epsilon RACK) or a TAT carrier control peptide and further treated with the same agents during isolation and in vitro for either 0, 1, 16, or 40 hours. Islet cells were assessed at each time point for viability, apoptosis, and function. psi epsilon RACK-treated islets showed significantly decreased islet cell death up to 40 hours after isolation compared with TAT-treated control islets. Beta-cell function in response to high glucose challenge remained unchanged.


Subject(s)
Cell Survival/physiology , Islets of Langerhans/cytology , Islets of Langerhans/enzymology , Protein Kinase C-epsilon/metabolism , Animals , Cell Culture Techniques , Cell Separation/methods , Diabetes Mellitus, Type 1/surgery , Enzyme Activation , Humans , Islets of Langerhans Transplantation , Male , Mice , Mice, Inbred BALB C , Tissue and Organ Harvesting/methods
13.
Am J Transplant ; 7(11): 2538-45, 2007 Nov.
Article in English | MEDLINE | ID: mdl-17908280

ABSTRACT

We conducted a randomized, multicenter study to determine whether treatment of subclinical rejection with increased corticosteroids resulted in beneficial outcomes in renal transplant patients receiving tacrolimus (TAC), mycophenolate mofetil (MMF) and prednisone. One hundred and twenty-one patients were randomized to biopsies at 0,1,2,3 and 6 months (Biopsy arm), and 119 to biopsies at 0 and 6 months only (Control arm). The primary endpoint of the study was the prevalence of the sum of the interstitial and tubular scores (ci + ct)> 2 (Banff) at 6 months. Secondary endpoints included clinical and subclinical rejection and renal function. At 6 months, 34.8% of the Biopsy and 20.5% of the Control arm patients had a ci + ct score >or= 2 (p = 0.07). Between months 0 and 6, clinical rejection episodes were 12 in 10 Biopsy arm patients and 8 in 8 Control arm patients (p = 0.44). Overall prevalence of subclinical rejection in the Biopsy arm was 4.6%. Creatinine clearance at 6 months was 72.9 +/- 21.7 in the Biopsy and 68.90 mL/min +/- 18.35 mL/min in the Control arm patients (p = 0.18). In conclusion, we found no benefit to the procurement of early protocol biopsies in renal transplant patients receiving TAC, MMF and prednisone, at least in the short term. This is likely due to their low prevalence of subclinical rejection.


Subject(s)
Kidney Transplantation/immunology , Kidney Transplantation/pathology , Mycophenolic Acid/analogs & derivatives , Tacrolimus/therapeutic use , Adult , Biopsy , Canada , Female , Graft Rejection/epidemiology , Graft Rejection/pathology , Humans , Immunosuppressive Agents/therapeutic use , Male , Middle Aged , Mycophenolic Acid/immunology , Patient Selection , Postoperative Period , Prednisone/therapeutic use , Prevalence , Time Factors
14.
Transplant Proc ; 37(2): 1211-3, 2005 Mar.
Article in English | MEDLINE | ID: mdl-15848672

ABSTRACT

INTRODUCTION: Modified release (MR) tacrolimus is an extended release formulation administered once daily. The purpose of this pharmacokinetic (PK) study was to evaluate tacrolimus exposure in stable liver transplant recipients converted from Prograf twice a day to MR tacrolimus once daily. METHODS: This was an open-label, multicenter study with a single sequence, four-period crossover design. Eligible patients were 18 to 65 years of age, >6 months posttransplant with stable renal and hepatic function and receiving stable doses of Prograf twice a day for >2 weeks prior to enrollment. Patients received Prograf twice a day on days 1 to 14 and 29 to 42. Patients were converted to the same milligram-for-milligram daily dose of MR once daily on days 15 to 28 and 43 to 56. Twenty-four-hour PK profiles were obtained on days 14, 28, 42, and 56. Laboratory and safety parameters were also evaluated. RESULTS: Of 70 patients, 62 completed all four PK profiles. The AUC0-24 of tacrolimus was comparable for Prograf twice a day (days 14 and 42) and MR tacrolimus once daily (days 28 and 56). The 90% confidence intervals for MR tacrolimus versus Prograf at steady state (days 28 and 56 vs days 14 and 42) was 0.85 to 0.92 for AUC0-24. MR tacrolimus was well tolerated with a safety profile comparable to that of Prograf. AUC0-24 was highly correlated to Cmin for Prograf (day 14, r = .93; Day 42, r = .89) and for MR tacrolimus (day 28, r = .93; day 56, r = .92). Renal and liver function remained stable. One patient experienced acute rejection. CONCLUSION: The steady-state tacrolimus exposure of MR tacrolimus once daily is equivalent to Prograf twice a day after a milligram-for-milligram conversion in stable liver transplant recipients.


Subject(s)
Immunosuppressive Agents/administration & dosage , Liver Transplantation/immunology , Tacrolimus/administration & dosage , Area Under Curve , Cross-Over Studies , Delayed-Action Preparations , Drug Administration Schedule , Humans , Immunosuppressive Agents/pharmacokinetics , Immunosuppressive Agents/therapeutic use , Metabolic Clearance Rate , Tacrolimus/pharmacokinetics , Tacrolimus/therapeutic use
16.
Ther Drug Monit ; 23(5): 520-5, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11591897

ABSTRACT

Mycophenolate mofetil (MMF), an immunosuppressant drug used in organ transplantation to prevent rejection, is being used increasingly in association with cyclosporine and tacrolimus. Mycophenolic acid (MPA) is primarily metabolized in the liver to its 7-O-glucuronide (MPAG) derivative. The concentrations of MPAG in serum are many times the concentrations of MPA. Although MPAG has not shown immunosuppressant activity, it was postulated that it could displace MPA from its binding sites on albumin and hence increase the biologic effects of MPA. This effect could be important for patients with acute renal failure; under this condition, MPAG was shown to accumulate. The goal of this study was to document the MPAG/MPA concentration ratio in 100 renal transplant patients under a mixed immunosuppressive therapy. Further, the study addressed the question of whether MPAG can displace MPA in vivo from bound albumin in a representative renal transplant patient population under immunosuppressive therapy. Levels of MPAG and MPA were measured by high-performance liquid chromatography. The distribution of the ratios was not parametric as it tailed toward elevated values. After a square root transformation of the data, parametric analysis was possible. The average MPAG/MPA ratio was 15.0 +/- 2.2 for men versus 7.7 +/- 0.9 for women. Men treated with MMF and tacrolimus showed a lower ratio than patients treated with MMF and cyclosporine, confirming that tacrolimus inhibits glucuronidation of MPA. Further, it was determined that at physiologic concentrations, MPAG does not increase the amount of free MPA. Because MPAG can favor the elimination of MPA, it can be concluded that gender differences and cotreatment with tacrolimus must be taken into consideration when MMF is being administered.


Subject(s)
Antibiotics, Antineoplastic/pharmacokinetics , Glucuronates/metabolism , Immunosuppressive Agents/pharmacokinetics , Kidney Transplantation/immunology , Mycophenolic Acid/analogs & derivatives , Mycophenolic Acid/metabolism , Mycophenolic Acid/pharmacokinetics , Sex Characteristics , Adult , Aged , Creatinine/metabolism , Cyclosporine/therapeutic use , Drug Monitoring , Drug Therapy, Combination , Female , Glucuronates/blood , Glucuronides , Humans , Immunosuppressive Agents/administration & dosage , Male , Middle Aged , Mycophenolic Acid/administration & dosage , Mycophenolic Acid/blood , Prospective Studies , Tacrolimus/therapeutic use
19.
Ann Chir ; 53(8): 687-9, 1999.
Article in French | MEDLINE | ID: mdl-10584376

ABSTRACT

Gingival Hyperplasia (GH) and hypertrichosis (HT) are two sides effects associated with the usage of cyclosporine (CyA) but not with tacrolimus (FK 506). The aim of this study is to evaluate the efficacy and security of the conversion from CsA to FK 506 to treat those two complications. From August 1996 to May 1997, 15 patients (9 males, 6 females) aged from 23 to 63 years old (38 +/- 14, mean +/- SD) were switched from CsA to FK 506, 12 for GH, 2 for HT and one for combined presentation. FK 506 was first initiated at a dose of 0.15 mg/kg/day and then adjusted to a level target of 8 ng/ml. The conversion was done on an out patient basis at average 35 (5-83) months after transplantation. Patients were followed prospectively for 12 months. There was a significant reduction in GH in all patients within 3 months. Five out 13 patients had a complete resolution of GH within three months of conversion, 9/12 within 6 months and all by 12 months. HT resolved completely within 6 months. No rejection episode occurred and the serum creatinin remain stable over one year post conversion. Conversion from CsA to FK 506 is thus a safe and valid option to treat CsA induced GH and HT.


Subject(s)
Cyclosporine/adverse effects , Gingival Hyperplasia/chemically induced , Hypertrichosis/chemically induced , Immunosuppressive Agents/adverse effects , Kidney Transplantation/immunology , Tacrolimus/therapeutic use , Adult , Creatinine/blood , Drug Monitoring , Female , Graft Rejection/prevention & control , Humans , Male , Middle Aged , Prospective Studies
20.
Arch Surg ; 134(1): 25-9, 1999 Jan.
Article in English | MEDLINE | ID: mdl-9927126

ABSTRACT

OBJECTIVE: To evaluate the effect of intraoperative transfusion of red blood cells (RBCs) on patient and graft survival. DESIGN: A retrospective study. SETTING: A tertiary care referral center. PATIENTS: Between January 1, 1992, and December 31, 1994, medical records from 225 adult patients who underwent primary liver transplantations were analyzed. RESULTS: Overall patient survival was 90% at 1 year and 86% at 3 years, while graft survival was 89% at 1 year and 85% at 3 years. The following factors were associated with patient and graft survival: age, sex, medical condition at the time of transplantation, and intraoperative transfusion of RBCs. When these factors were subjected to a multivariate analysis, all were independently associated with survival. Fifty-four recipients (24%) underwent transplantation without intraoperative transfusion of RBCs, while 171 recipients (76%) received at least 1 U of RBCs intraoperatively. Recipients who did not receive transfusion of RBCs had higher patient and graft survival rates than patients who did receive RBCs. By multivariate analysis, transplantation without intraoperative transfusion of RBCs no longer remained statistically significant, and only sex and the patient's medical condition were independently associated with patient and graft survival. Patient and graft survival decreased if 5 or more U were transfused, but transfusion of 5 or more U was not independently associated with survival by multivariate analysis. CONCLUSIONS: Increased transfusion requirement for RBCs was independently associated with patient and graft survival. While transplantation without transfusion of intraoperative RBCs was associated with superior patient and graft survival, these effects were overridden by patient sex and medical condition at the time of transplantation.


Subject(s)
Erythrocyte Transfusion , Intraoperative Care , Liver Transplantation , Female , Graft Survival , Humans , Liver Transplantation/mortality , Male , Middle Aged , Retrospective Studies , Survival Rate , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...